Zafgen, Inc. to Present at Upcoming Conferences
Zafgen, Inc. to Present at Upcoming Conferences
March 25, 2009 at 12:00 AM EDT
Zafgen, Inc. to Present at Upcoming Conferences
About Zafgen, Inc.
Zafgen is the first biopharmaceutical company dedicated to developing novel obesity therapeutics that directly target and shrink fat tissue to help the body regain and sustain a lean, healthy state. Adipose tissue (fat) is composed primarily of cells that store unused calories, as well as an extensive network of blood vessels that support the tissue. The nature of the tissue and the interplay between fat cells and the supporting blood vessels play a critical and active role in determining the overall size of the fat tissue, and therefore, an individual’s weight. Zafgen’s groundbreaking approach targets obesity at its root cause by safely manipulating and shrinking the blood supply to fat tissue, driving the loss of fat and a return to a more healthy body weight. Zafgen's leadership and scientific advisors include the leading experts in obesity, metabolic disorders and medicinal chemistry. Founded in 2005, the company is located in Cambridge, Massachusetts. For more information, visit www.zafgen.com.
Cambridge, MA, March 25, 2009 – Zafgen, Inc., a private venture-backed biopharmaceutical
company focused on developing novel obesity therapeutics, today announced that Dr. Thomas
Hughes, Ph.D., president and chief executive officer, will present a company overview at several
upcoming conferences.
- BIO National Venture Conference in Boston on April 1, 2009 at 11:15 a.m. EST
- BioCentury Future Leaders in the Biotech Industry Conference in New York City on April 2, 2009 at 11:30 a.m. EST
- Boston Biotech Business Development Conference in Boston on April 7, 2009 at 9:00 a.m. EST
About Zafgen, Inc.
Zafgen is the first biopharmaceutical company dedicated to developing novel obesity therapeutics that directly target and shrink fat tissue to help the body regain and sustain a lean, healthy state. Adipose tissue (fat) is composed primarily of cells that store unused calories, as well as an extensive network of blood vessels that support the tissue. The nature of the tissue and the interplay between fat cells and the supporting blood vessels play a critical and active role in determining the overall size of the fat tissue, and therefore, an individual’s weight. Zafgen’s groundbreaking approach targets obesity at its root cause by safely manipulating and shrinking the blood supply to fat tissue, driving the loss of fat and a return to a more healthy body weight. Zafgen's leadership and scientific advisors include the leading experts in obesity, metabolic disorders and medicinal chemistry. Founded in 2005, the company is located in Cambridge, Massachusetts. For more information, visit www.zafgen.com.